Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{205518,
        author = {Vivek Rai},
        title = {NANOPARTICLE-BASED DRUG DELIVERY FOR CANCER THERAPY},
        journal = {International Journal of Innovative Research in Technology},
        year = {2026},
        volume = {13},
        number = {1},
        pages = {7005-7013},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=205518},
        abstract = {Nanoparticle-based drug delivery systems have emerged as a transformative strategy in cancer therapy by improving drug solubility, enhancing targeted delivery, reducing systemic toxicity, and overcoming multidrug resistance. Conventional chemotherapy often lacks specificity, leading to adverse side effects and limited therapeutic efficacy. Nanotechnology offers innovative approaches for precise drug delivery through engineered nanoparticles such as liposomes, polymeric nanoparticles, dendrimers, metallic nanoparticles, and lipid-based carriers. These systems can exploit passive targeting through the enhanced permeability and retention (EPR) effect and active targeting using ligands directed toward tumor-specific receptors. This review discusses the principles, types, mechanisms, applications, advantages, limitations, and future prospects of nanoparticle-based drug delivery systems in cancer treatment. Cancer remains one of the leading causes of morbidity and mortality worldwide and continues to pose a major challenge to global healthcare systems despite remarkable progress in diagnostic and therapeutic approaches. Conventional cancer treatment strategies such as chemotherapy, radiotherapy, surgery, hormone therapy, and immunotherapy have significantly improved patient survival rates; however, these approaches are frequently associated with several serious limitations including poor drug selectivity, severe systemic toxicity, nonspecific biodistribution, multidrug resistance, rapid drug degradation, limited therapeutic index, and damage to healthy tissues. Among these, conventional chemotherapy remains one of the most widely used modalities for cancer treatment, but its lack of specificity often results in harmful side effects such as cardiotoxicity, nephrotoxicity, neurotoxicity, immunosuppression, and gastrointestinal complications. Consequently, there is an urgent need for advanced therapeutic systems capable of delivering anticancer agents more safely and effectively while minimizing adverse effects on normal tissues.},
        keywords = {Nanoparticles; Cancer therapy; Drug delivery systems; Targeted drug delivery; Nanomedicine; Liposomes; Polymeric nanoparticles.},
        month = {June},
        }